Pharmaceutical standardization of Antardhooma Rasasindura and comparison of its therapeutic effect with Bahirdhooma Rasasindura along with Guduchi Ghana in the management of Madhumeha (Type 2 Diabetes)

IPGT and RA0 个研究点目标入组 50 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Patients having chief & associated complains of Madhumeha (Prabhuta-Avilmutrata, pipasadhikya, kshudhadhikya etc)
•Patients having Fasting blood sugar level ? 126 mg/dl and or PPBS level ? 200 mg/dl
•Known patients of Type2 Diabetes and also the preliminarily diagnosed patients on the basis of signs and symptoms of the disease are confirmed by FBS and PPBS.

•Age more than 60 and below 30 years
•Pramehapidaka (Diabetic nonhealing wound), Systemic infection, active infection other than superficial mild skin infestation
•Secondary Diabetes mellitus.
•Patients of any other severe illness.
•Type 1 Diabetes
•Malignant and accelerated hypertensive.
•Other chronic debilitating diseases.
•Pregnant woman and expecting conception (within six month)
•Lactating mothers.
•Patients with fatal diabetic complication like end stage renal disease
•Patient with diabetic ketoacidosis, diabetic nephropathy and neuropathy.
•Patients on Insulin and are dire need of it, patients taking OHA other than Metformin.

发起方

IPGT and RA